Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + azacitidine with dose-adjusted HAG double induction for relapsed/refractory acute myeloid leukemia
ChiCTR1900026095Phase 4Not yet recruiting
- Sponsor
- The Peoples' Hospital of Jiaozuo City
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax, azacitidine, homoharringtonine, cytarabine and granulocyte colony-stimulating factor in acute myeloid leukemia (AML), sponsored by The Peoples' Hospital of Jiaozuo City. Primary endpoints: Complete blood count, Bone marrow cytology and 1 more. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
venetoclaxazacitidinehomoharringtoninecytarabinegranulocyte colony-stimulating factor
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR1900026095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026095.